血清CA19-9、CA125及CEA检测在胰腺癌化疗病人诊断及预后中的临床意义分析  

ANALYSIS OF CLINICAL SIGNIFICANCE OF SERUM CA19-9,CA125 AND CEA TESTING IN DIAGNOSIS AND PROGNOSIS OF CHEMOTHERAPY PATIENTS WITH PANCREATIC CANCER

作　　者：王佩[1] 

机构地区：[1]河南新乡市中心医院肿瘤科,新乡453000

出　　处：《现代预防医学》2011年第23期5036-5037,5039,共3页Modern Preventive Medicine

摘　　要：[目的]了解血清CA19-9、CA125及CEA水平变化与胰腺癌化疗疗效的相关性,及其在判断胰腺癌化疗预后的应用价值。对照分析生存期≥7.5个月组与﹤7.5个月组及胰腺癌进展组与未进展组CA19-9、CA125及CEA检查值。[方法]选择2009年1月-2010年12月收治53例胰腺癌患者。用双抗体夹心ABC-ELISA法测定血清中CA19-9、CA125及CEA含量。[结果]生存期≥7.5个月的患者,血清CEA、CA19-9和CA125检测值显著低于与﹤7.5个月的患者(P﹤0.05)。胰腺癌进展组患者血清CEA、CA19-9和CA125检测值显著高于与未进展组(P﹤0.05)。[结论]血清CEA、CA19-9和CA125检测值和胰腺癌患者化疗疗效及生存期呈正相关性。[Objective]To understand the correlation of CA19 serum CA125 and CEA level change and curative effect of pancreatic cancer chemotherapy,and its application value in judging prognosis of pancreatic cancer chemotherapy.[Methods]53 patients with pancreatic cancer that were treated in our department between January 2007 and December 2008 were selected.Comparatively analyzed the values of CA19-9,CA125 and CEA of these patients[Results]The values of CA19-9,CA125 and CEA of patients with life span ≥7.5 months were significantly lower than that of patients with life span ﹤7.5 months（P﹤0.05）.Check values of CA19-9,CA125 and CEA of patients with progress pancreatic cancer were higher than that patients with progression-free pancreatic cancer（P﹤0.05）.[Conclusion]The values of serum CEA,CA19-9 and CA125 have the positively correlation with life span and prognosis of chemotherapy patients with pancreatic cancer.

关 键 词：胰腺癌 化疗 CA19-9 CA125 CEA 

分 类 号：R735.9[医药卫生—肿瘤]